EP3575326
Meðhöndlun á CD47+ sjúkdómsfrumum með SIRP-alfa-Fc samrunum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
17.12.2013EP published:
13.4.2022EP application number:
19185175.7
EP translation filed:
2.6.2022Grant published:
15.7.2022EPO information:
European Patent Register
Max expiry date:
16.12.2033Expiry date:
16.12.2026Next due date:
31.12.2026
Title in English:
TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONSLanguage of the patent:
English
Timeline
Today
17.12.2013EP application
13.4.2022EP Publication
2.6.2022Translation submitted
15.7.2022Registration published
16.12.2026Expires
Owner
Name:
Pfizer Inc.Address:
66 Hudson Boulevard East, New York, NY 10001-2192, US
Inventor
Name:
UGER, Robert AdamAddress:
Richmond Hill, Ontario L4C 7S4, CA
Name:
SLAVOVA-PETROVA, Penka SlavtchevaAddress:
Toronto, Ontario M8V 3X1, CA
Name:
PANG, XinliAddress:
Brampton, Ontario L6R 3H1, CA
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201261738008 PDate:
17.12.2012Country:
US
Classification
Categories:
C07K 19/00, A61K 38/16, A61K 38/45, A61P 35/02, C07K 14/705, C07K 16/00, C12N 15/62, A61K 38/00
Annual fees
Number
Paid
Expires
Payer
Number: 10
Paid: 31.10.2022
Expires: 16.12.2023
Payer: Árnason Faktor ehf.
Number: 11
Paid: 15.11.2023
Expires: 16.12.2024
Payer: Árnason Faktor ehf.
Number: 12
Paid: 11.11.2024
Expires: 16.12.2025
Payer: Árnason Faktor ehf.
Number: 13
Paid: 9.12.2025
Expires: 16.12.2026
Payer: Árnason Faktor ehf.